These nearly 50 product candidates include numerous innovative bispecific antibodies, such as odronextamab, ivonescimab, linvoseltamab, zenocutuzumab, and erfonrilimab, and antibody-drug conjugates, such as trastuzumab botidotin, patritumab deruxtecan, datopotamab deruxtecan, and MRG002, as ...
2 免疫检查点与PD-1/PD-L1抗体 ImmunecheckpointandPD-1/PD-L1antibody 3 PD-1/PD-L1抑制剂现状 CurrentstatusofPD-1/PD-L1inhibitors 4 问题与展望 ProblemsandProspects 肿瘤免疫治疗TumorImmunotherapy 肿肿瘤瘤免免疫疫疗疗法法的的分现类状 肿瘤免疫疗法的原理和分类PrinciplesandClassificationofTumorImmunotherapy...
ThedevelopmentprocessofsmallmoleculeinhibitorsofimmunecheckpointPD-1/PD-L1,asanimportanttargetfortumorimmunotherapy,hasgonethroughmultiplestages.Earlyresearchmainlyfocusedonthedevelopmentofmacromolecularantibodydrugs,whichhaveshownsignificanttherapeuticeffectsinclinicaltrials.However,therearealsoissuessuchashighproductioncosts...
Anti-PD-L1/CD40 bispecific antibody (Harbour BioMed)、HBM 9027、HBM9027 靶点 CD40 x PDL1 作用机制 CD40抑制剂(肿瘤坏死因子受体超家族成员5抑制剂)、PDL1抑制剂(程序性死亡配体1抑制剂) 治疗领域 肿瘤 在研适应症 晚期恶性实体瘤实体瘤 非在研适应症- ...
In various embodiments of the present invention, the antibody is a fully human PD-L1 antibody binding. 在某些实施方案中,本发明提供了多特异性抗原结合分子,其包含与PDL1结合的第一结合特异性和与肿瘤细胞抗原,感染细胞特异性抗原或T细胞共抑制剂结合的第二结合特异性. In certain embodiments, the present ...
抗体-药物缀合物(antibody-drug conjugate)(adc)技术是靶导向技术,其允许选择性杀死或抑制癌细胞的生长或分裂。通常,adc通过利用抗体靶向癌细胞和然后在细胞中释放毒性物质(即药物)而起作用,由此引发细胞死亡。由于adc技术允许将药物准确地递送到靶癌细胞并在特定条件下释放,同时最小化对健康细胞的附带损伤,所以adc技...
④Cancer Immunology Research:T Cells Expressing a Modified FcγRI Exert Antibody-Dependent Cytotoxicity and Overcome the Limitations of CAR T-cell Therapy against Solid Tumors 基于FcγRI结构表达修饰的T细胞发挥抗体依赖性细胞毒性并克服CAR-T细胞在实体瘤领域的局限性 ...
Antibody-Drug Conjugates as Novel Therapeutic Agents for Non-Small Cell Lung Carcinoma with or without Alterations in Oncogenic Drivers In metastatic non-small cell lung carcinoma (NSCLC) without alterations in oncogenic drivers, platinum-based chemotherapy and immune checkpoint inhibitors (ICIs) targeting...
S. et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515, 563–567 (2014). CAS PubMed PubMed Central Google Scholar Chen, G. et al. Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature...
anti-PD-L1 antibody (αPD-L1), and hedgehog pathway antagonist vismodegib, to eradicate residual tumor cells while promoting bone regeneration post-surgery. In a mouse model of tibia osteosarcoma, this hydrogel-mediated combination therapy led to remarkable tumor growth inhibition and hence increased ...